2017年10月3日，复星医药正式完成并购Gland Pharma，自此复星医药大家庭中又新增海外成员，加快国际化进程。新年伊始，我们采访了Gland Pharma COO Mr. Srinivas Sadu，旨在从公司管理层角度探索公司企业文化与未来发展，增进企业间融合与交流，助力双方携手共创更高成就。
Gland Pharma
COO
Mr. Srinivas Sadu
对话Mr. Srinivas Sadu
Q
作为企业COO，您觉得Gland Pharma最让您骄傲的是什么？为什么？
As COO of Gland Pharma, what makes you proud of Gland Pharma ? And why ?
Mr. Srinivas Sadu：My journey at Gland Pharma began in the year 2000, when the company was contemplating setting up theexports division. What I witnessed then were the - Entrepreneurial spirit, Quality consciousness, Operational freedom, & Team spirit - seeded within the company’s DNA, which has over the years stood strong and has helped provide years of phenomenal growth. Even today when I look at the company’s team and the work culture, the same spirit continues to live and it helps provide greater accountability, enormous freedom to take up additional responsibilities and a continuous restlessness to excel at our work. I am proud that we were able to build a company which in itself has imbibed what I would call a culture to “Never Give Up” while maintaining the highest standards of quality and ethics. While we take utmost care to bring the right talent, with the correct culturalfit into the organization, I must say that this team is ready to take the company into the next phase of the growth trajectory.
我与Gland Pharma结缘于2000年，当时公司正在考虑设立出口部门。一直以来，企业家精神、质量理念、运营的自由度与团队精神都深深植根在公司的DNA中，强有力地助力公司多年卓越成长。即使在今天，公司团队和工作文化的精神风貌依然如初，鼓励员工承担更多、更大的责任，促进我们在工作中不断进步。让我感到骄傲的是，我们建立了一个倡导“永不放弃”精神的企业，并保持着最高标准的质量准则和道德标准。当我们尽最大的努力把能够融入我们企业文化的适合人才引进团队时，我必须说，我们的团队已经做好充足的准备带领公司进入下一个成长阶段。
Gland Pharma生产制造基地
Q
在与复星医药合作过程中，复星医药团队给你最深印象的是什么？为什么？
During the cooperation with Fosun Pharma team, what leaves the deepest impression? Why?
Mr. Srinivas Sadu：Firstly I would like to say that the leadership at Fosun Pharma is truly inspirational in all rights. During our several interactions over the past two years, there is no ambiguity that they are not just exceptional managers but also have experience of building companies from a verynascent stage. They have a vision where they see a world full of possibilities,with so much to achieve and at a pace which is no way constrained by the access to resources. While being aggressive in their decisions, they continue to have that humane touch which stands out as a virtue of a true leader.
We had the opportunity and pleasure to host a broader group from Fosun Pharma during recent times and the employees connected exceptionally well both culturally and professionally. Glad to see that the team from Fosun Pharma was very open to the ideas/thoughts shared and had the urge to learn& share, which stands out and speaks highly of the value system.
I truly believe that the Fosun-Gland “One-Team” has much greater heights to achieve!
首先，我想说的是，复星医药团队的领导力确实非常鼓舞人心。在过去两年的几次互动中，让我坚信不疑的是他们不仅是出色的职业经理人，而且具有从创业到管理公司的丰富经验。复星医药团队是具有远见的，他们深信世界充满无限可能性，并不断探索资源、不断超越。他们锐意进取，又不失人文关怀，这让他们出类拔萃，成为真正的领导者。
最近，我们荣幸接待了来自复星医药各条线的员工团队，双方有机会在工作和企业文化交流中互相学习融通。复星医药团队拥有开放的心态，乐于接受思想碰撞、学习与分享；他们的价值体系卓尔不群，值得称赞。
复星医药管理团队到访Gland Pharma
我深信，秉持“一个团队”的精神，复星医药和Gland Pharma将会携手共创更高的成就。
Q
您对Gland Pharma与复星医药的合作有何期待？未来，您希望双方如何进一步合作，助力双方更好地发展？
In your opinion, what do you expect cooperating with Fosun Pharma? How could Gland Pharma strengthen integration for mutual better development through its collaboration with Fosun Pharma?
Mr. Srinivas Sadu：There are many synergies that Fosun Pharma&GlandPharma are currently working on, which will unlock a lot of value in the monthsto come.
In terms of strategic positioning, Gland Pharma can be the common platform of Injectables and Ophthalmics (Manufacturing and R&D)for Fosun Pharma.Added to this Gland Pharma will also be a global platform for ANDA registrations and ANDA sales for Fosun Pharma. Gland will lead the business operations for Fosun Pharma in India and shall also form a dedicated techno-commercial team to help optimize and evaluate business cases for Fosun Pharma.
Gland Pharma will benefit significantly by getting access to new geographies including the Chinese market which otherwise has very highentry barrier. Gland will leverage Fosun Pharma’s strength in M&A to help give access to new markets or haveniche product offerings. The integration of R&D will help Gland look at new product evaluations with a global view and significantly increase the product offerings.
I will emphasize that the scale, resources, and technology platforms which Fosun Pharma possesses, presents Gland Pharma aunique opportunity in the global injectable industry to grow and cater to a much holistic value chain!
目前，复星医药和Gland Pharma在业务上有许多协同，并将会在未来为双方创造更多的价值。
在战略层面，Gland Pharma将成为复星医药注射剂研发生产基地，同时，也将成为复星医药ANDA注册和销售的国际化平台。Gland Pharma将作为复星医药在印度市场开拓的主力，建立一支科技引领、促进商业运营的团队。
与复星医药的合作，将有益于推动Gland Pharma进入新市场领域，包括准入门槛非常高的中国市场。Gland Pharma将借助复星医药在并购整合方面的优势，助力开拓新市场并获得更多产品市场供应。另外，复星医药在研发方面的整合能力将帮助Gland Pharma以全球视野进行新产品评估，并显著提升产品的市场供应。
我想强调的是，复星医药的规模、资源和技术平台为Gland Pharma 在全球注射剂行业提供了独一无二的机会，使其能够不断发展，并形成一个整体的价值链。
